Market Cap 189.87M
Revenue (ttm) 82.03M
Net Income (ttm) -65.78M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -80.19%
Debt to Equity Ratio 0.00
Volume 554,700
Avg Vol 488,854
Day's Range N/A - N/A
Shares Out 28.42M
Stochastic %K 2%
Beta 2.40
Analysts Strong Sell
Price Target $17.88

Company Profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address orni...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 900 2660
Address:
10285 Science Center Drive, San Diego, United States
wahoowa96
wahoowa96 Mar. 18 at 1:09 PM
$ARCT Time to go chief.
0 · Reply
notreload_ai
notreload_ai Mar. 18 at 11:48 AM
B. Riley starts coverage on $ARCT with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs. https://notreload.xyz/arcturus-therapeutics-stands-out-in-mrna-space-b-riley-initiates-buy/
0 · Reply
bigchouse
bigchouse Mar. 18 at 12:06 AM
$ARCT Per Brave's browser AI technologies: Jerome Powell is scheduled to speak following the Federal Open Market Committee (FOMC) meeting on Wednesday, March 18, 2026, at 2:30 p.m. ET. The press conference will be held after the Fed announces its interest rate decision, with the policy statement released at 2:00 p.m. ET. The event will be available via live stream on the Federal Reserve’s official website and YouTube channel.
0 · Reply
Newbilly
Newbilly Mar. 17 at 8:05 PM
$ARCT about time to add tomm
0 · Reply
Newcar
Newcar Mar. 17 at 4:30 PM
$ARCT There is no confidence in this company, investors are skeptical about its success, that's why it collapsed and never recovered.
0 · Reply
wahoowa96
wahoowa96 Mar. 17 at 2:01 PM
$ARCT Hey Cathie can you send some reinforcement if you're still believer?
1 · Reply
bigchouse
bigchouse Mar. 17 at 1:47 PM
$ARCT xAI NEWS: Paul Conyngham, a Sydney-based tech entrepreneur and AI consultant, used Grok to finalize a mRNA vaccine construct for his dog Rosie's mast cell cancer. Paul used three AI models. He combined ChatGPT for initial ideas, AlphaFold for mutation analysis, and Grok took the mutation data and other inputs to create the final sequence for the custom mRNA vaccine targeting those exact mutations. Paul sequenced Rosie's healthy DNA and the tumor DNA for $3,000 at the University of New South Wales' (UNSW) Ramaciotti Research Centre, in Sydney, Australia. He partnered with researchers like Prof. Pall Thordarson and Prof. Martin Smith for manufacturing and injection. They reported a 75% shrinkage in one tumor. https://x.com/SERobinsonJr/status/2033610892928032864#m
1 · Reply
Newcar
Newcar Mar. 17 at 1:44 PM
$ARCT waiting for 5$
0 · Reply
bigchouse
bigchouse Mar. 17 at 8:08 AM
$ARCT A federal judge on Monday blocked Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s changes to vaccine policy, including the reduction of the recommended childhood immunizations and his remaking of a key vaccine advisory panel. https://thehill.com/policy/healthcare/5786565-judge-blocks-kennedy-vaccine-changes/
0 · Reply
DragonAlgo
DragonAlgo Mar. 17 at 6:50 AM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-04-17 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.45 Stop: $0.32 TP1: $0.59 TP2: $0.77 TP3: $1.08 🔗 https://dragonalgo.com
0 · Reply
Latest News on ARCT
Arcturus Therapeutics to Attend Upcoming Investor Conference

Mar 5, 2026, 9:00 AM EST - 13 days ago

Arcturus Therapeutics to Attend Upcoming Investor Conference


Arcturus Therapeutics to Attend Upcoming Investor Conferences

Nov 4, 2025, 4:01 PM EST - 4 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences


Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.


wahoowa96
wahoowa96 Mar. 18 at 1:09 PM
$ARCT Time to go chief.
0 · Reply
notreload_ai
notreload_ai Mar. 18 at 11:48 AM
B. Riley starts coverage on $ARCT with Buy, praising its standout lipid-enabled mRNA platform for cystic fibrosis (ARCT-032) and OTC deficiency (ARCT-810) programs. https://notreload.xyz/arcturus-therapeutics-stands-out-in-mrna-space-b-riley-initiates-buy/
0 · Reply
bigchouse
bigchouse Mar. 18 at 12:06 AM
$ARCT Per Brave's browser AI technologies: Jerome Powell is scheduled to speak following the Federal Open Market Committee (FOMC) meeting on Wednesday, March 18, 2026, at 2:30 p.m. ET. The press conference will be held after the Fed announces its interest rate decision, with the policy statement released at 2:00 p.m. ET. The event will be available via live stream on the Federal Reserve’s official website and YouTube channel.
0 · Reply
Newbilly
Newbilly Mar. 17 at 8:05 PM
$ARCT about time to add tomm
0 · Reply
Newcar
Newcar Mar. 17 at 4:30 PM
$ARCT There is no confidence in this company, investors are skeptical about its success, that's why it collapsed and never recovered.
0 · Reply
wahoowa96
wahoowa96 Mar. 17 at 2:01 PM
$ARCT Hey Cathie can you send some reinforcement if you're still believer?
1 · Reply
bigchouse
bigchouse Mar. 17 at 1:47 PM
$ARCT xAI NEWS: Paul Conyngham, a Sydney-based tech entrepreneur and AI consultant, used Grok to finalize a mRNA vaccine construct for his dog Rosie's mast cell cancer. Paul used three AI models. He combined ChatGPT for initial ideas, AlphaFold for mutation analysis, and Grok took the mutation data and other inputs to create the final sequence for the custom mRNA vaccine targeting those exact mutations. Paul sequenced Rosie's healthy DNA and the tumor DNA for $3,000 at the University of New South Wales' (UNSW) Ramaciotti Research Centre, in Sydney, Australia. He partnered with researchers like Prof. Pall Thordarson and Prof. Martin Smith for manufacturing and injection. They reported a 75% shrinkage in one tumor. https://x.com/SERobinsonJr/status/2033610892928032864#m
1 · Reply
Newcar
Newcar Mar. 17 at 1:44 PM
$ARCT waiting for 5$
0 · Reply
bigchouse
bigchouse Mar. 17 at 8:08 AM
$ARCT A federal judge on Monday blocked Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s changes to vaccine policy, including the reduction of the recommended childhood immunizations and his remaking of a key vaccine advisory panel. https://thehill.com/policy/healthcare/5786565-judge-blocks-kennedy-vaccine-changes/
0 · Reply
DragonAlgo
DragonAlgo Mar. 17 at 6:50 AM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-04-17 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.45 Stop: $0.32 TP1: $0.59 TP2: $0.77 TP3: $1.08 🔗 https://dragonalgo.com
0 · Reply
bigchouse
bigchouse Mar. 17 at 6:18 AM
$ARCT Lots of buying at the end of the day. Shorts have covered. Time to bounce.
0 · Reply
Newcar
Newcar Mar. 16 at 4:22 PM
$ARCT They are trying everything to try to get the positive data out😅
1 · Reply
wahoowa96
wahoowa96 Mar. 13 at 10:55 PM
$ARCT WTI to Zero is coming... thought oil was a new gold 😂? Iran won't ever play a nuke again. https://www.theguardian.com/world/live/2026/mar/13/iran-war-news-live-updates-us-israel-middle-east-crisis-latest
0 · Reply
MaxCorona
MaxCorona Mar. 13 at 3:46 PM
$ARCT but today Ill get my cheap shares. No possible incomes for years, only cash for 1-2 years. After that offering, pennystock…But in 4-5 maybe profitable. Or buncrupt. So thats a real long time invest…but Ill keep and buy when cheap. Gambling, not more
1 · Reply
DragonAlgo
DragonAlgo Mar. 13 at 12:12 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-03-20 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.25 Stop: $0.18 TP1: $0.33 TP2: $0.42 TP3: $0.60 Risk preset by model constraints. 🔗 https://dragonalgo.com
0 · Reply
Choice79
Choice79 Mar. 12 at 7:15 PM
$ARCT also measuring LCI and life improvements is going to be quite impactful. Just measuring FEV doesn’t take into account reduced mucus plugs etc. improved quality of life is a key measure not taken into account with FEV.
0 · Reply
wahoowa96
wahoowa96 Mar. 12 at 5:03 PM
$ARCT From yesterda's chat on 032. It seems screening is all there's left from starting 032 12-weeks extended phase 2. Rock it and go for accelerated approval! "Payne also said Arcturus is narrowing baseline lung function eligibility criteria compared with the earlier approach of enrolling subjects across a wide baseline range (he referenced “40 to 100”). The company, he said, is targeting a “sweet spot” of patients who are neither too high-functioning nor too advanced in disease, to improve the likelihood of detecting a treatment effect over 12 weeks."
1 · Reply
wahoowa96
wahoowa96 Mar. 12 at 5:00 PM
$ARCT I really like the stricter volunteer screening with no baseline swings like ARCT chipmunk traders' wild sp swings...and finding patients with a stabilized initial baseline with a reasonable advance status. If the progression was less than 30% there were complete wipe out of all the plugs but didn't show meaningful ppFEV changes because the deterioration was not there to improve much on ...but the 032 is still worth in a preventative sense...#5 patient was very good one and Arcturus need 20 of #5's. If the initial 5 days were somehow forgiving to allow average on those initial FEV values to establish initial FEV value that confidence interval shrinks to a tighter band to defeat any arguments that any improvement of 7-14% were just part of the noise within the confidence interval band. If Arcturus and FDA live with that 5 days becoming day 0 I think we have a good trend with #5 population.
0 · Reply
Nganlm
Nganlm Mar. 12 at 9:43 AM
$ARCT Hi to all those interested: this write up provides the fireside chat… https://www.marketbeat.com/instant-alerts/arcturus-therapeutics-teases-12-week-phase-2-cf-study-after-well-tolerated-inhaled-mrna-dosing-2026-03-12/
1 · Reply
King316
King316 Mar. 11 at 9:38 PM
$ARCT **Short summary of main content topics** from Arcturus Therapeutics' Fireside Chat (Leerink Partners 2026 Global Healthcare Conference, March 11, 2026): - **Cystic Fibrosis program** (main focus): Advances in inhaled mRNA therapy (ARCT-032), targeting lung function gains (e.g., FEV1), ongoing FDA/EMA talks for regulatory path, trial design, & potential fast-track options in rare diseases. - **Rare disease pipeline**: Emphasis on liver/respiratory indications (incl. OTC deficiency), powered by LUNAR® delivery & STARR® self-amplifying mRNA for better dosing/expression. - **CSL Seqirus partnership**: Brief note as active collaboration on sa-mRNA vaccines (flu, COVID); platform validation via approved KOSTAIVE® (Japan); no new milestones/data/changes shared. - **Broader strategy/finance**: Reaffirmed focus on rare diseases, solid cash to reach key milestones; positive, forward-looking tone without major surprises.
0 · Reply
Nganlm
Nganlm Mar. 11 at 7:07 PM
$ARCT Just listened to the fireside chat at the Leerink Partners 2026 Global Healthcare Conference by CEO Joe Payne. Very informative and the arbitration with CSL was mentioned. Do go in to listen.
2 · Reply
DragonAlgo
DragonAlgo Mar. 11 at 12:50 PM
🐉 $ARCT CALL — DragonAlgo® Signal Contract: ARCT CALL Expiry: 2026-03-20 | Strike: $7.50 | Type: CALL Option Plan (premium): Entry: $0.50 Stop: $0.36 TP1: $0.65 TP2: $0.85 TP3: $1.20 Rules-based execution profile. 🔗 https://dragonalgo.com
0 · Reply